Karachiwala, Hatim
Cross Cancer Institute
2 papers on CoChatORCID 0000-0001-9375-2882
Most cited papers
- Verified
Nivolumab plus ipilimumab versus lenvatinib or sorafenib as first-line treatment for unresectable hepatocellular carcinoma (CheckMate 9DW): an open-label, randomised, phase 3 trial
Yau, T., Galle, P. R., Decaens, T., Sangro, B., Qin, S., da Fonseca, L. G., Karachiwala, H., Blanc, J.-F., Park, J.-W., Gane, E., et al. (2025) · The Lancet
Hepatocellular Carcinoma Treatment and PrognosisCancer Immunotherapy and Biomarkers
Cited by 390
- Verified
Real‐world experience of tyrosine kinase inhibitors in children, adolescents and adults with relapsed or refractory bone tumours: A Canadian Sarcoma Research and Clinical Collaboration (CanSaRCC) study
Peretz Soroka, H., Vora, T., Noujaim, J., Marcoux, N., Cohen‐Gogo, S., Alcindor, T., Holloway, C., Rodrigues, C., Karachiwala, H., Alvi, S., et al. (2023) · Cancer Medicine
Sarcoma Diagnosis and TreatmentBone Tumor Diagnosis and Treatments
Cited by 17
Go further with a free account
Verify every reference, keep papers in a library, and ask questions across them.
Sign up - it is free